105 related articles for article (PubMed ID: 30119948)
1. Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry.
Huang TC; Huang SY; Yao M; Lin CY; Hwang WL; Gau JP; Tan TD; Wang PN; Liu YC; Lin SC; Kao RH; Pei SN; Yu MS; Lin HY; Su YC; Chen CC; Li SS; Wu YY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):471-480. PubMed ID: 30119948
[TBL] [Abstract][Full Text] [Related]
2. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response.
Lehners N; Becker N; Benner A; Pritsch M; Löpprich M; Mai EK; Hillengass J; Goldschmidt H; Raab MS
Cancer Med; 2018 Feb; 7(2):307-316. PubMed ID: 29282899
[TBL] [Abstract][Full Text] [Related]
3. Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting.
Garrido D; Bove V; Villano F; Riva E
Acta Medica (Hradec Kralove); 2023; 66(3):117-121. PubMed ID: 38511422
[TBL] [Abstract][Full Text] [Related]
4. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang EC; Muffly LS; Shiraz P; Shizuru JA; Johnston L; Arai S; Frank MJ; Weng WK; Lowsky R; Rezvani A; Meyer EH; Negrin R; Miklos DB; Sidana S
Transplant Cell Ther; 2021 May; 27(5):405.e1-405.e6. PubMed ID: 33775587
[TBL] [Abstract][Full Text] [Related]
5. Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis.
Suzuki K; Gunji T; Kawashima M; Uryu H; Nagao R; Momoki M; Yokoyama H; Ishii H; Tanoue S; Saito T; Nishiwaki K; Yano S
Int J Hematol; 2024 Jan; 119(1):39-49. PubMed ID: 38103160
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation.
Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Tang G; Kebriaei P; Aljawai Y; Khan HN; Lee HC; Ye C; Patel KK; Thomas SK; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Blood Cancer J; 2024 May; 14(1):82. PubMed ID: 38760362
[TBL] [Abstract][Full Text] [Related]
7. Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis.
Tangen JM; Tjønnfjord GE; Gulbrandsen N; Gedde-Dahl T; Stormorken E; Anderson K; Vo CD; Schjesvold FH;
BMC Cancer; 2018 Aug; 18(1):801. PubMed ID: 30089450
[TBL] [Abstract][Full Text] [Related]
8. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Alzahrani K; Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin R; Qazilbash MH
Br J Haematol; 2024 May; 204(5):1944-1952. PubMed ID: 38448009
[TBL] [Abstract][Full Text] [Related]
9. The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma.
Salafian K; Mazimba C; Volodin L; Varadarajan I; Pilehvari A; You W; Knio ZO; Ballen K
Bone Marrow Transplant; 2024 Apr; 59(4):459-465. PubMed ID: 38238453
[TBL] [Abstract][Full Text] [Related]
10. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.
Derman BA; Jasielec J; Langerman SS; Zhang W; Jakubowiak AJ; Chiu BC
Blood Cancer J; 2020 Aug; 10(8):80. PubMed ID: 32770051
[TBL] [Abstract][Full Text] [Related]
11. Early M-protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma.
Zhu H; Liu J; Gu J; Chen M; Kuang L; Huang B; Zou W; Li J
Br J Haematol; 2024 Mar; 204(3):976-987. PubMed ID: 38246862
[TBL] [Abstract][Full Text] [Related]
12. Recent trends in incidence, survival and treatment of multiple myeloma in Finland - a nationwide cohort study.
Ruotsalainen J; Lehmus L; Putkonen M; Lievonen J; Kallio A; Raittinen P; Summanen M; Kosunen M; Korhonen MJ
Ann Hematol; 2024 Apr; 103(4):1273-1284. PubMed ID: 38085293
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Garderet L; Gras L; Koster L; De Wreede L; Montserrat R; Vincent L; Fenk R; Karunanithi K; Deeren D; Kaufmann M; Kuball J; Ozdogu H; Cascon MJP; Passweg J; Rye A; Salmenniemi U; Snowden J; Hansen CT; Leleu X; Gastaud L; Sokolowska JD; Raj K; Beksac M; Schönland S; Hayden P; McLornan D
Haematologica; 2024 Mar; ():. PubMed ID: 38546696
[TBL] [Abstract][Full Text] [Related]
14. Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.
Giles HV; Drayson MT; Kishore B; Pawlyn C; Kaiser M; Cook G; de Tute R; Owen RG; Cairns D; Menzies T; Davies FE; Morgan GJ; Pratt G; Jackson GH
Blood Cancer J; 2024 Mar; 14(1):50. PubMed ID: 38499538
[TBL] [Abstract][Full Text] [Related]
15. AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes.
Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238501
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
Jin X; Jiang X; Li H; Shen K; Liu S; Chen M; Yang C; Han B; Zhuang J
Acta Haematol; 2024 Apr; ():. PubMed ID: 38626745
[TBL] [Abstract][Full Text] [Related]
17. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
Guo W; Strouse C; Mery D; Siegel ER; Munshi MN; Ashby TC; Cheng Y; Sun F; Wanchai V; Zhang Z; Bailey C; Alapat DV; Peng H; Al Hadidi S; Thanendrarajan S; Schinke C; Zangari M; van Rhee F; Tricot G; Shaughnessy JD; Zhan F
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539451
[TBL] [Abstract][Full Text] [Related]
18. PHF19 before and post induction treatment possess favorable potency of reflecting treatment response to protease inhibitors, event-free survival, and overall survival in multiple myeloma patients.
An H; Chen S; Zhang X; Ke S; Ke J; Lu Y
Hematology; 2024 Dec; 29(1):2331389. PubMed ID: 38511642
[TBL] [Abstract][Full Text] [Related]
19. Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma.
Halpin SN; Konomos M; Jowers I
J Patient Exp; 2021; 8():2374373521998864. PubMed ID: 34179409
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.
Gandolfi S; Vekstein C; Laubach JP; O'Brien A; Masone K; Munshi NC; Anderson KC; Richardson PG
Clin Adv Hematol Oncol; 2018 Aug; 16(8):564-574. PubMed ID: 30148829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
